Vitamina E Sherfarma

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vitamina E Sherfarma

Property Description
Active Ingredient alpha-Tocopherol (Vitamin E)
Form Soft Capsules (cápsulas blandas)
Pharmacological Class Fat-Soluble Vitamin, Antioxidant
General Purpose Correcting deficiency, Cell Protection
Origin Natural (d-alpha-tocopherol) or Synthetic (dl-alpha-tocopherol)

Vitamina E Sherfarma is classified as a pharmaceutical preparation and dietary supplement containing the essential fat-soluble vitamin, alpha-Tocopherol. This product is primarily a source of Vitamin E, an essential micronutrient that the body cannot produce and which must be obtained through the diet or supplementation. The medicine's identity is defined by its role as a powerful protective agent against cellular stress.


1. Defining Vitamina E Sherfarma: Classification and Core Ingredient

Vitamina E Sherfarma belongs to the Pharmacological Class of Fat-Soluble Vitamins and is simultaneously categorized as an Antioxidant. The sole active ingredient is alpha-Tocopherol (INN), which is clinically recognized as the most biologically active form of Vitamin E utilized by the human body. This classification highlights the preparation's function: delivering a necessary vitamin required for maintaining various physiological processes, particularly cellular defense.

The selective retention and transport of alpha-Tocopherol ensure it is the form that fulfills human nutritional requirements, distinguishing it from other tocopherols. This is a crucial differentiation point for the substance, making it the primary target for supplementation aimed at correcting nutritional status.


2. What is the Composition and Form of the Product?

The preparation is typically presented in the dosage form of soft capsules (cápsulas blandas) and is designated for oral route of administration. The active ingredient is often provided as the stable derivative, Tocopheryl acetate, dissolved in a fatty oil base or lipophilic vehicle. This oil base is crucial because Vitamin E is fat-soluble, meaning it must be consumed with fats to be properly absorbed through the intestine. The alpha-Tocopherol may be sourced as natural (d-alpha-tocopherol) or as a synthetic racemic mixture (dl-alpha-tocopherol), with the natural form generally demonstrating a higher biological potency.


3. General Purpose: Why is Alpha-Tocopherol Important?

The general purpose of Vitamina E Sherfarma is to act as a Cell Protector by utilizing the ingredient's core Antioxidant capabilities. Its primary physiological effect is to function as a chain-breaking antioxidant that actively neutralizes unstable molecules called free radicals within the body. This protective action is critical because it helps prevent oxidative damage, specifically stopping the destruction of cell membranes and lipids. Ultimately, the product's general benefit centers on supporting tissue integrity and maintaining the structural health of cells against internal destructive processes.

Regulatory References

  1. MedlinePlus

What side effects are possible with Vitamina E Sherfarma?

Possible side effects and safety information

The description of potential side effects and safety characteristics for alpha-Tocopherol (Vitamina E Sherfarma) is based strictly on regulatory classifications and documented patterns from official government sources.

Adverse reactions are primarily associated with high-dose supplementation (e.g., above 400 IU/day) and long-term exposure, rather than typical dietary intake. The frequency of many effects is often not known or cannot be established from the available data.


System-Organ Classes and Adverse Reactions

The non-serious adverse effects reported in regulatory documents typically involve the following system-organ classes:

  • Gastrointestinal Disorders: May include diarrhea, nausea, stomach cramps, and abdominal pain.
  • Nervous System Disorders: Reactions can include the onset of headache and dizziness.
  • General Disorders and Eye Disorders: Systemic symptoms such as unusual tiredness or weakness and blurred vision have been documented in association with high-dose, prolonged use.

Serious Safety Considerations

The most significant safety characteristic documented in official information is the increased risk of bleeding (hemorrhage). This risk is related to the anti-platelet activity of high-dose alpha-Tocopherol and its potential to interfere with Vitamin K function.

This constraint necessitates specific safety considerations:

  • Interaction Risk: The potential to enhance the effects of concomitant Anticoagulants (such as warfarin) or Antiplatelet agents, thereby raising the risk of bleeding, is officially noted.
  • Vulnerable Populations: Caution is explicitly noted in regulatory documents for patients with pre-existing Vitamin K deficiency or known Bleeding Disorders.

Overdose and Emergency Response

Overdose and when to seek help

The information regarding overdose manifestations for alpha-Tocopherol (Vitamin E) is based on official government regulatory documents, which classify the potential signs and required emergency actions.

Overdose, especially resulting from long-term, high-dose ingestion, may present with several documented clinical manifestations. These can include gastrointestinal disturbances such as diarrhea and abdominal pain, as well as general symptoms like headache, dizziness, fatigue, and blurred vision.

The most significant and severe documented outcome associated with overdose is the risk of bleeding (haemorrhage), due to the substance's effect on blood clotting factors. This risk is notably increased for individuals concurrently taking anticoagulant medications (e.g., warfarin).

Mandatory Emergency Actions

Official labeling mandates that urgent medical attention must be sought for any suspected overdose. Immediate emergency services (911) should be contacted if the person exhibits critical symptoms such as seizures, trouble breathing, collapse, or inability to be awakened.

In all cases of suspected overdose, a poison control center should be contacted immediately. Medical attention should be sought right away if any signs of unusual bleeding or bruising occur.

There is no specific antidote known for alpha-Tocopherol overdose. Treatment focuses on symptomatic and general supportive care, which includes discontinuing the supplement.

Therapeutic Uses of Vitamina E Sherfarma

Vitamina E Sherfarma (alpha-tocopherol) is commonly used to address and manage Vitamin E deficiency and its related symptomatic consequences.

This product is used to address clinically confirmed Vitamin E deficiency, which frequently stems from underlying fat malabsorption disorders.

What Vitamina E Sherfarma Treats: Main Uses and Benefits

Vitamina E Sherfarma is commonly applied in clinical settings to address conditions such as cystic fibrosis, chronic cholestatic liver disease, and rare genetic transport disorders, in situations where supplementation with this essential nutrient may be appropriate. This therapy is relevant in contexts involving heightened systemic burden, as it supports managing symptoms that create noticeable physiological strain on the body.

The product is specifically used for managing neuromuscular dysfunction (like muscle weakness and balance issues), peripheral neuropathy, and sight problems such as retinopathy that may emerge from severe, prolonged deficiency. This supportive action may assist with maintaining functional stability and supports general well-being during symptomatic phases. It provides support that helps ease the overall symptom burden associated with the deficit.

“This therapy may be part of symptomatic management in situations where the body cannot properly utilize fat-soluble vitamins, offering supportive relief.”

Quick Fact: Relief for Neuromuscular Strain

This supplementation is relevant for its role in supporting neurological function and alleviating physiological strain in deficiency contexts.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Eligibility and Restrictions

Vitamina E Sherfarma, based on its active ingredient alpha-Tocopherol, is officially allowed for individuals with confirmed Vitamin E deficiency, particularly those with fat malabsorption disorders such as cystic fibrosis or chronic liver disease. Use is established in both adults and children for deficiency treatment, though pediatric use requires adherence to specific age-based maximum daily intake levels.


Contraindications and High-Dose Restrictions

Use is contraindicated in patients with a known hypersensitivity to any component of the formulation. The use of high doses (typically ge 400 IU/day) is significantly restricted and cautioned against in certain populations due to regulatory warnings:

Population Status Restriction Type
Patients taking oral anticoagulants (e.g., Warfarin) High-Dose Restriction (Increased risk of bleeding)
Patients with Retinitis Pigmentosa High-Dose Prohibition (Risk of disease acceleration)
Patients with a history of stroke or myocardial infarction High-Dose Caution (Associated with increased risk)

Pregnancy and Lactation

Use is permitted during pregnancy and breastfeeding at nutritional (Recommended Dietary Allowance) levels. However, high-dose supplementation is not recommended due to a lack of established safety data above the Tolerable Upper Intake Level (UL).

What should I know about interactions with other medicines?

The official interaction profile for Vitamina E Sherfarma (alpha-Tocopherol) is defined by its effects on anti-clotting processes and alterations to drug absorption, as documented in government regulatory sources. These interactions are broadly classified as Pharmacodynamic Reinforcement and Pharmacokinetic Alterations.

Interaction Type Interacting Agents (Examples) Official Outcome (Regulatory Statement)
Pharmacodynamic Reinforcement Anticoagulants (e.g., Warfarin), Antiplatelets, Garlic, Ginkgo Increased risk of hemorrhage due to additive anti-clotting activity.
Reduced Vitamin E Exposure Orlistat, Colestyramine, Anticonvulsants (e.g., Phenytoin), Oral Contraceptives Reduction of Vitamin E plasma concentrations or gastrointestinal absorption.
Altered Co-Drug Levels Iron-containing products (e.g., Ferrous Sulfate) Vitamin E decreases the absorption and subsequent levels of these agents.

The product’s regulatory labeling dictates a specific timing-based interaction rule: the drug Orlistat must be administered two hours before or two hours after Vitamina E Sherfarma to mitigate reduced absorption. Furthermore, the anti-clotting effect is officially noted to be exaggerated in patients with Vitamin K deficiencies, such as those associated with liver failure, necessitating particular caution. This official interaction profile is structured around the product's essential fat-soluble nature and its known antagonism of Vitamin K.

Mechanism of Action

How Vitamina E Sherfarma Works: Mechanism of Action

Vitamina E Sherfarma (alpha-tocopherol) exerts its effects primarily through two key biological mechanisms: cellular protection and pathway modulation. The molecule's actions are focused on chemical stabilization and regulation within specific cell systems.


Antioxidant Protection of Cellular Structures

This domain describes the molecule's role as a fat-soluble antioxidant localized within cell membranes. The active component acts as a free radical scavenger by terminating the lipid peroxidation cascade, a process that damages the fatty components of the cell structure. This mechanism is fundamental to the maintenance of structural integrity and lipid fluidity of membranes across cells, including nerve cells and red blood cells.


Modulation of Intracellular Signaling

This domain addresses the molecule's influence on intracellular signaling pathways and enzyme activity, which are vital for cell-to-cell communication and regulatory processes. The mechanism influences cellular activity within systems governing immune cell function and vascular endothelial dynamics. By affecting these pathways, the molecule modulates mechanisms related to cell proliferation and influences processes that determine microvascular dynamics.

Dosage and Administration Information

The usage of alpha-Tocopherol, the active ingredient in Vitamina E Sherfarma, is formally defined based on the specific clinical need. The preparation is designated for oral administration, typically provided as a soft capsule formulation, to address confirmed deficiency states. The standard schedule involves once- or twice-daily dosing, a frequency designed to sustain consistent alpha-tocopherol concentrations within the body.

The precise dosage is highly individualized and is determined by the underlying disorder causing the deficiency, rather than a single fixed standard. While lower daily doses address mild deficiencies, high-dose regimens may involve weight-based calculations, sometimes reaching 50 mg to 100 mg per kilogram per day, and are reserved for severe malabsorption conditions like Abetalipoproteinemia.

A core requirement for proper administration is that the capsule must be ingested with or immediately after a fat-containing meal. This contextual instruction is critical because alpha-Tocopherol is a fat-soluble compound, and the presence of dietary fat is necessary for adequate intestinal absorption. The established protocol for all patients involves long-term use with mandatory periodic laboratory monitoring of serum alpha-tocopherol levels. This monitoring governs subsequent dose adjustments, ensuring the protocol remains appropriate over the duration of the underlying condition.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Early Research and Potential Action

Research has focused on exploring the drug's potential interaction with specific biological pathways involved in the inflammatory response. Early-stage preclinical and Phase I studies focused on identifying potential therapeutic activity and evaluating how the drug is metabolized in the body.

Clinical Trial Findings

Clinical development has progressed through multiple phases, primarily investigating the drug for chronic musculoskeletal conditions.

Phase II Study Outcomes

A collection of Phase II, randomized, controlled studies investigated whether there is an association with changes in joint function and inflammation in adults with diagnosed chronic inflammatory conditions. These studies were instrumental in determining the appropriate study parameters for further investigation.

  • One study, involving 250 participants, assessed the occurrence of adverse events across three different regimens over a 12-week period.
  • Another study evaluated the impact on participant-reported pain scales and biomarkers of inflammation. The focus was on determining if a signal of activity was present to support further large-scale trials.

Phase III Study Outcomes

Larger Phase III trials were designed to further evaluate the drug's potential effects and safety profile across a broader patient population.

  • Pain Management Focus: Studies investigated whether the drug may be associated with outcomes in managing mild to moderate pain related to chronic inflammatory conditions. One multi-center trial with 800 participants compared the drug's outcomes against standard over-the-counter pain relievers over six months.
  • Symptom Duration: Studies also examined whether the combination is associated with changes in the duration of flare-ups in a subgroup of participants.
  • Safety and Adverse Events: Safety and tolerability have been evaluated in adult populations. The most frequently reported events were documented in trials, and these findings informed the full safety profile assessment.

Long-term Research

The long-term effects of this approach on symptom relief are an area of ongoing study. Long-term extension studies are being conducted to monitor the safety and durability of outcomes over one to two years.

Frequently Asked Questions (FAQ)

Common questions about Vitamina E Sherfarma (FAQ)


Q: Is Vitamina E Sherfarma a prescription medication or can I buy it over the counter?

A: Official information indicates that Vitamin E is widely available for purchase without a prescription (over the counter). However, for addressing confirmed deficiency states, healthcare providers may also prescribe it at specific, tailored doses.


Q: Can Vitamina E Sherfarma be used by pregnant women, based on official information?

A: Regulatory guidelines establish a Recommended Dietary Allowance (RDA) and a Tolerable Upper Intake Level (UL) for Vitamin E during pregnancy. While taking the recommended dietary amount is generally not expected to increase risk, the use of prescribed or high doses is clinically managed.


Q: Are there any known interactions between Vitamina E Sherfarma and birth control pills?

A: Official regulatory information notes that Oral Contraceptives may be associated with a reduction in the body's absorption or plasma concentrations of Vitamin E. The interaction is one factor considered by the prescribing healthcare professional.


Q: What should I do if I experience a rare or serious side effect mentioned in the official leaflet?

A: Official guidance documents emphasize that serious side effects, such as unusual bleeding or bruising, are reported to a healthcare provider for clinical review. The most significant safety characteristic documented is the potential for an increased risk of hemorrhage.


Q: Can Vitamina E Sherfarma affect laboratory test results?

A: Regulatory-related clinical documents indicate that serum bilirubin levels may be increased with the use of Vitamin E. This highlights the importance of laboratory monitoring, particularly when high-dose supplementation is used for prolonged periods, as noted in the core product information.


Q: Is Vitamina E Sherfarma the same as tocopherol acetate?

A: The active ingredient in the preparation is alpha-Tocopherol. It is often provided in a stable derivative form called Tocopheryl acetate, which is chemically related and widely used in formulations. Tocopheryl acetate is readily converted into the active form (alpha-Tocopherol) by the body.


Q: What is the role of Vitamina E Sherfarma in managing conditions related to cell damage?

A: The molecule functions as a chain-breaking antioxidant that prevents oxidative damage, specifically by protecting the fatty components of cell membranes from unstable molecules called free radicals. The molecule’s role is described as maintaining the structural health of cells against internal destructive processes.


Q: Why do some sources describe Vitamina E Sherfarma as being used for nervous system support?

A: The drug's mechanism of action includes maintaining the structural integrity and lipid fluidity of nerve cells because it is a fat-soluble antioxidant. Official sources note that primary Vitamin E deficiency is commonly associated with neurological disorders, such as a loss of coordination.


Q: Is there any research evidence supporting the use of Vitamina E Sherfarma for heart health?

A: Regulatory-affiliated research reviews indicate that while some experimental evidence suggests benefits for heart health, the findings from clinical trials regarding this use are currently under review by the scientific community and have not led to official recommendations. The primary regulatory use remains correcting deficiency.


Q: What happens if you accidentally take more Vitamina E Sherfarma than the prescribed amount?

A: The official Tolerable Upper Intake Level (UL) for supplemental alpha-tocopherol is set at 1,000 mg per day for adults, based on the documented adverse effect of an increased tendency to hemorrhage. Intake exceeding the UL is a matter for immediate clinical evaluation.


Q: What is the source of the vitamin E in Vitamina E Sherfarma (e.g., natural or synthetic)?

A: Official documentation notes that the alpha-Tocopherol may be sourced as the natural form (labeled d-alpha-tocopherol) or as a synthetic racemic mixture (labeled dl-alpha-tocopherol). The natural form is sometimes defined by regulatory bodies as having a greater biological activity.


Q: Can Vitamina E Sherfarma interact with herbal supplements like St. John's wort?

A: Official warnings require patients to inform their healthcare provider about all prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products they are taking. This review is conducted to identify potential interactions.


Q: Is Vitamina E Sherfarma suitable for use in children?

A: Official guidelines provide specific Adequate Intakes and Tolerable Upper Intake Levels for various pediatric age groups. Special considerations and lower dose limits are explicitly noted in regulatory-affiliated documents for vulnerable groups like preterm neonates.


Q: If I already take a multivitamin, is it safe to also take Vitamina E Sherfarma?

A: Official guidance describes that the healthcare provider considers the total intake of Vitamin E from all sources (diet, multivitamin, and prescription product) in relation to the Tolerable Upper Intake Level (UL) established by regulatory bodies.


Q: Is there official information about Vitamina E Sherfarma's use during breastfeeding?

A: Official guidelines provide a Recommended Dietary Allowance (RDA) and Tolerable Upper Intake Level (UL) for lactating women. Vitamin E is a normal component of breast milk, and women are generally advised to continue meeting their daily recommended amount while breastfeeding.


Q: What are the known potential interactions with anti-seizure medications?

A: The official interaction profile lists Anticonvulsants (such as phenytoin) as agents that may cause a reduction of Vitamin E plasma concentrations or impaired gastrointestinal absorption. The clinical management of this interaction may involve monitoring.


Q: Are there any official warnings about driving or operating machinery while using Vitamina E Sherfarma?

A: The documented side effects include dizziness and blurred vision, which are effects that may impair concentration and coordination. Guidance documents note that if these side effects occur, caution in performing tasks like driving or operating machinery is a factor for clinical consideration.


Q: What is the meaning of 'prophylactic use' in relation to Vitamina E Sherfarma?

A: The term prophylactic use refers to taking the preparation to prevent a condition from developing. Official information notes the use of Vitamin E supplementation to prevent deficiency in specific patient populations, such as individuals with certain digestive diseases that cause malabsorption.


Q: Can Vitamina E Sherfarma be used by individuals with kidney problems?

A: Regulatory-related clinical guidance notes that patients with renal impairment (kidney problems) are generally monitored closely. Some specific formulations may carry a documented risk of renal toxicity due to the presence of excipients, such as polyethylene glycol.


Q: What does official guidance say about discontinuing Vitamina E Sherfarma use?

A: Official guidance describes that any cessation of a dose being taken for a specific medical condition is generally a matter for consultation with a healthcare provider. This ensures appropriate management of the underlying condition.


Q: Why is Vitamina E Sherfarma often discussed in relation to fertility?

A: Regulatory-affiliated resources note that Vitamin E deficiency might be associated with men producing less sperm, which could affect fertility. This link to reproductive system health is a common topic of inquiry in scientific and patient communities.


Q: Is there any research suggesting Vitamina E Sherfarma affects the immune system?

A: The drug's mechanism of action includes Modulation of Intracellular Signaling, which is officially noted to influence activity within systems governing immune cell function. This suggests a regulatory role in maintaining normal immune processes.


Q: Are there different strengths or formulations of Vitamina E Sherfarma available?

A: Vitamin E is commercially available in multiple forms, including soft capsules, gel capsules, and oral solutions or liquid drops. Different strengths are also manufactured to accommodate the wide range of dose requirements necessary to address varying deficiency levels.


Q: Can Vitamina E Sherfarma be split or crushed, or must it be swallowed whole?

A: The most common form, the soft capsule, is generally intended to be swallowed whole. However, official information notes that oral solutions or liquid drops are also available, and these are often described as being mixed with food or juice for administration.


Q: Is there any evidence linking Vitamina E Sherfarma use to specific long-term risks?

A: The most significant long-term risk documented in official information, associated primarily with high-dose and prolonged use, is the increased risk of bleeding (hemorrhage). This risk is related to the drug's potential to interfere with Vitamin K function.

How should Vitamina E Sherfarma be stored and disposed of?

How to Store and Dispose of Vitamina E Sherfarma

The storage of Vitamina E Sherfarma soft capsules (alpha-Tocopherol acetate) is strictly defined to maintain product stability. The medication must be stored at Controlled Room Temperature, which is typically 20 C to 25 C.

Storage and Handling

The capsules must be protected from light and excessive heat and stored in their original, tight, light-resistant container. It is a mandatory requirement to keep the product out of the reach of children.

Disposal Instructions

Official regulatory guidelines require that unused or expired capsules must be disposed of in accordance with local regulations (e.g., via pharmacy take-back programs). The medication must not be emptied into drains, wastewater, or household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vitamina E Sherfarma found in:

A-Z Index: